LEADER 02789nam 2200625 a 450 001 9910461238703321 005 20200520144314.0 010 $a1-283-49176-1 010 $a9786613491763 010 $a0-8213-8932-7 035 $a(CKB)2670000000151682 035 $a(EBL)868329 035 $a(OCoLC)778463087 035 $a(SSID)ssj0000621525 035 $a(PQKBManifestationID)11386119 035 $a(PQKBTitleCode)TC0000621525 035 $a(PQKBWorkID)10616944 035 $a(PQKB)10020795 035 $a(MiAaPQ)EBC868329 035 $a(Au-PeEL)EBL868329 035 $a(CaPaEBR)ebr10535699 035 $a(CaONFJC)MIL349176 035 $a(EXLCZ)992670000000151682 100 $a20110923d2012 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aDraining development?$b[electronic resource] $econtrolling flows of illicit funds from developing countries /$fedited by Peter Reuter 210 $aWashington, D.C. $cWorld Bank$d2012 215 $a1 online resource (552 p.) 300 $aDescription based upon print version of record. 311 $a0-8213-8869-X 320 $aIncludes bibliographical references and index. 327 $apt. 1. The political economy of illicit flows -- pt. 2. Illegal markets -- pt. 3. To what extent do corporations facilitate illicit flows? -- pt. 4. Policy interventions -- pt. 5. Conclusions and the path forward. 330 $aA growing concern among those interested in economic development is the realization that hundreds of billions of dollars are illicitly flowing out of developing countries to tax havens and other financial centers in the developed world. This volume assesses the dynamics of these flows, much of which is from corruption and tax evasion. What causes them, what are their consequences and how might they be controlled? The chapters by authors from a variety of backgrounds, including criminologists and practicing lawyers as well as economists, examine many dimensions of the phenomenon. For example, 606 $aTax administration and procedure$zDeveloping countries 606 $aMoney laundering$zDeveloping countries 606 $aTax evasion$zDeveloping countries 606 $aTransfer pricing$xTaxation$xLaw and legislation$zDeveloping countries 608 $aElectronic books. 615 0$aTax administration and procedure 615 0$aMoney laundering 615 0$aTax evasion 615 0$aTransfer pricing$xTaxation$xLaw and legislation 676 $a364.1/33 701 $aReuter$b Peter$f1944-$0121153 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910461238703321 996 $aDraining development$92105310 997 $aUNINA LEADER 01359nam0 22003011i 450 001 UON00193713 005 20231205103225.489 010 $a35-330-4064-X 100 $a20030730d1988 |0itac50 ba 101 $amul 102 $aDE 105 $a|||| ||||| 200 1 $aˆDie ‰ Laryngaltheorie und die Rekonstruktion des indogermanischen Laut- und Formensystems$fhrsg. von Alfred Bammesberger 210 $aHeidelberg$cWinter$d1988. 585 p. ; 25 cm. 410 1$1001UON00088057$12001 $aIndogermanische Bibliothek. Dritte Reihe$eUntersuchungen$fhrsg. von Alfred Bammesberger 606 $aFONOLOGIA$3UONC024819$2FI 606 $aLINGUE GERMANICHE ANTICHE$3UONC040264$2FI 606 $aLINGUE INDOEUROPEE$xFonetica$3UONC040265$2FI 620 $aDE$dHeidelberg$3UONL000174 676 $a491$cLINGUE ORIENTALI$v21 702 1$aBAMMESBERGER$bAlfred$3UONV056914 712 $aWinter Universitätsverlag$3UONV260404$4650 801 $aIT$bSOL$c20241115$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00193713 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI Ling 43 Smarrito $eSI LO 58967 5 $sSmarrito 996 $aLaryngaltheorie und die Rekonstruktion des indogermanischen Laut- und Formensystems$91292640 997 $aUNIOR LEADER 04625nam 2201213z- 450 001 9910619467203321 005 20221025 010 $a3-0365-5281-2 035 $a(CKB)5670000000391602 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/93194 035 $a(oapen)doab93194 035 $a(EXLCZ)995670000000391602 100 $a20202210d2022 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aBrain-Targeted Drug Delivery 210 $cMDPI - Multidisciplinary Digital Publishing Institute$d2022 215 $a1 online resource (260 p.) 311 08$a3-0365-5282-0 330 $aBrain diseases currently affect one in six people worldwide; they include a wide range of neurological diseases, from Alzheimer's and Parkinson's diseases to epilepsy, brain injuries, brain cancer, neuroinfections, and strokes. The treatment of these diseases is complex and limited due to the presence of the blood-brain barrier (BBB), which covers the entirety of the brain. The BBB not only has the function of protecting the brain from harmful substances; it is also a metabolic barrier and a transport regulator of nutrients/serum factors/neurotoxins. Knowing these characteristics when it comes to the treatment of brain diseases makes it easier to understand the lack of efficacy of therapeutic drugs, resulting from the innate resistance of the BBB to permeation. To overcome this limitation, drug delivery systems based on nanotechnology/microtechnology have been developed. Brain-targeted drug delivery enables targeted therapy with a higher therapeutic efficacy and fewer side effects because it targets moieties present in the drug delivery systems. 606 $aTechnology: general issues$2bicssc 610 $a3D cell culture systems 610 $aacetaminophen 610 $aAlzheimer's disease 610 $aAlzheimer's disease-relevant tau species 610 $aanti-tau and anti-receptor bispecific monoclonal antibodies 610 $ablood-brain barrier 610 $ablood-brain barrier 610 $abrain biodistribution 610 $abrain cancer 610 $abrain targeted therapy 610 $acentral composite rotatable design 610 $acerebral open flow microperfusion 610 $acerebrospinal fluid microcirculation 610 $achemoattractant 610 $aclaudin-5 610 $aCNS drug delivery 610 $aconvection-enhanced delivery 610 $aCXCL 610 $aCXCR 610 $adelivery to brain 610 $adepression 610 $adiffuse midline glioma 610 $adrug delivery 610 $adrug delivery into the brain 610 $aelectrochemical biosensors 610 $aGB-13 610 $agene therapy 610 $aglioblastoma 610 $aglioblastoma multiforme 610 $aglycol chitosan 610 $ahigh-grade glioma 610 $ahyaluronidase 610 $aIL-13 610 $aIL-13R?2 610 $aIL13.E13K-PE4E 610 $aimmunotherapy 610 $aimmunotoxin 610 $aimproved memory 610 $ainteractions between A? and tau 610 $aintranasal delivery 610 $alaser 610 $aliposome 610 $amacromolecules 610 $amemory impairment 610 $amicrodialysis 610 $amicroparticles 610 $amovement impairment 610 $an/a 610 $ananoparticle 610 $ananoparticles 610 $ananostructured lipid carrier 610 $anaringenin 610 $anasal delivery system 610 $aneurosurgery 610 $anon-human primate 610 $anose to brain delivery 610 $aopioids 610 $aoptogenetics 610 $aParkinson's disease 610 $aphospholipid oily gel 610 $aPLGA 610 $apolyplexes 610 $apomegranate seed oil 610 $areceptor expression 610 $aseizure 610 $atargeted therapy 610 $atau clearance in microglia 610 $atau clearance in neurons 610 $atemporal-spatial pathological A? and tau distribution 610 $atight junction 610 $atolcapone 610 $atransendothelium based on receptor-mediated transcytosis 610 $aultrasound 615 7$aTechnology: general issues 700 $aSousa$b Fla?via$4edt$01323094 702 $aSousa$b Fla?via$4oth 906 $aBOOK 912 $a9910619467203321 996 $aBrain-Targeted Drug Delivery$93035376 997 $aUNINA